## Ioannis U Isaias

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4096618/publications.pdf

Version: 2024-02-01

81900 106344 4,778 102 39 65 citations g-index h-index papers 105 105 105 5290 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Adaptive deep brain stimulation: Retuning Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 273-284.	1.8	11
2	A Fully-Immersive Virtual Reality Setup to Study Gait Modulation. Frontiers in Human Neuroscience, 2022, 16, 783452.	2.0	10
3	Rodent models for gait network disorders in Parkinson's disease – a translational perspective. Experimental Neurology, 2022, 352, 114011.	4.1	9
4	Clinical and genetic correlations of scoliosis in Rett syndrome. European Spine Journal, 2022, 31, 2987-2993.	2.2	1
5	Troubleshooting Gait Disturbances in Parkinson's Disease With Deep Brain Stimulation. Frontiers in Human Neuroscience, 2022, 16, .	2.0	6
6	Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus. Movement Disorders, 2021, 36, 124-132.	3.9	22
7	Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus. Neurology, 2021, 96, e2861-e2873.	1.1	18
8	Impaired reach-to-grasp kinematics in parkinsonian patients relates to dopamine-dependent, subthalamic beta bursts. Npj Parkinson's Disease, 2021, 7, 53.	<b>5.</b> 3	14
9	Dermal and cardiac autonomic fiber involvement in Parkinson's disease and multiple system atrophy. Neurobiology of Disease, 2021, 153, 105332.	4.4	17
10	Towards adaptive deep brain stimulation: clinical and technical notes on a novel commercial device for chronic brain sensing. Journal of Neural Engineering, 2021, 18, 042002.	3.5	56
11	The sensitivity of ECG contamination to surgical implantation site in brain computer interfaces. Brain Stimulation, 2021, 14, 1301-1306.	1.6	43
12	Safety and Effectiveness of Cell Therapy in Neurodegenerative Diseases: Take-Home Messages From a Pilot Feasibility Phase I Study of Progressive Supranuclear Palsy. Frontiers in Neuroscience, 2021, 15, 723227.	2.8	1
13	Vocal cord electromyographic correlates of stridor in multiple system atrophy phenotypes. Parkinsonism and Related Disorders, 2020, 70, 31-35.	2.2	6
14	Bilateral pallidal stimulation improves cervical dystonia for more than a decade. Parkinsonism and Related Disorders, 2020, 81, 78-81.	2.2	15
15	Gait-related frequency modulation of beta oscillatory activity in the subthalamic nucleus of parkinsonian patients. Brain Stimulation, 2020, 13, 1743-1752.	1.6	42
16	Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy. Npj Parkinson's Disease, 2020, 6, 39.	5.3	8
17	Gait initiation in progressive supranuclear palsy: brain metabolic correlates. NeuroImage: Clinical, 2020, 28, 102408.	2.7	21
18	Brain metabolic alterations herald falls in patients with Parkinson's disease. Annals of Clinical and Translational Neurology, 2020, 7, 579-583.	3.7	9

#	Article	IF	Citations
19	Gait Initiation in Parkinson's Disease: Impact of Dopamine Depletion and Initial Stance Condition. Frontiers in Bioengineering and Biotechnology, 2020, 8, 137.	4.1	32
20	Deep brain stimulation: a review of the open neural engineering challenges. Journal of Neural Engineering, 2020, 17, 051002.	<b>3.</b> 5	50
21	Freezing of gait in Parkinson's disease reflects a sudden derangement of locomotor network dynamics. Brain, 2019, 142, 2037-2050.	7.6	96
22	Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient. Movement Disorders, 2019, 34, 757-759.	3.9	28
23	A New Scale to Evaluate Motor Function in Rett Syndrome: Validation and Psychometric Properties. Pediatric Neurology, 2019, 100, 80-86.	2.1	16
24	Sit-to-walk performance in Parkinson's disease: A comparison between faller and non-faller patients. Clinical Biomechanics, 2019, 63, 140-146.	1.2	22
25	Probabilistic mapping of the antidystonic effect of pallidal neurostimulation: a multicentre imaging study. Brain, 2019, 142, 1386-1398.	7.6	105
26	Motor function in Rett syndrome: comparing clinical and parental assessments. Developmental Medicine and Child Neurology, 2019, 61, 957-963.	2.1	15
27	Excitability of the supplementary motor area in Parkinson's disease depends on subcortical damage. Brain Stimulation, 2019, 12, 152-160.	1.6	35
28	PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time. Annals of Nuclear Medicine, 2019, 33, 69-77.	2.2	10
29	Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. Npj Parkinson's Disease, 2018, 4, 11.	<b>5.</b> 3	169
30	Dopamine reuptake transporter–singleâ€photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	3.9	25
31	SPECT Molecular Imaging in Atypical Parkinsonism. International Review of Neurobiology, 2018, 142, 37-65.	2.0	7
32	Disrupt of Intra-Limb APA Pattern in Parkinsonian Patients Performing Index-Finger Flexion. Frontiers in Physiology, 2018, 9, 1745.	2.8	7
33	Phase matters: A role for the subthalamic network during gait. PLoS ONE, 2018, 13, e0198691.	2.5	38
34	Cortical response to levodopa in Parkinson's disease patients with dyskinesias. European Journal of Neuroscience, 2018, 48, 2362-2373.	2.6	9
35	Cholinergic activity and levodopaâ€induced dyskinesia: a multitracer molecular imaging study. Annals of Clinical and Translational Neurology, 2017, 4, 632-639.	3.7	15
36	Reply: Clinical approach to delayed-onset cerebellar impairment following deep brain stimulation for tremor. Brain, 2017, 140, e28-e28.	7.6	5

#	Article	IF	CITATIONS
37	<i>Mucuna pruriens</i> in Parkinson disease. Neurology, 2017, 89, 432-438.	1.1	79
38	Beta Oscillatory Changes and Retention of Motor Skills during Practice in Healthy Subjects and in Patients with Parkinson's Disease. Frontiers in Human Neuroscience, 2017, 11, 104.	2.0	49
39	Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease. Frontiers in Aging Neuroscience, 2016, 8, 196.	3.4	146
40	Striatal Dopaminergic Innervation Regulates Subthalamic Beta-Oscillations and Cortical-Subcortical Coupling during Movements: Preliminary Evidence in Subjects with Parkinson's Disease. Frontiers in Human Neuroscience, 2016, 10, 611.	2.0	45
41	Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. Journal of the Neurological Sciences, 2016, 365, 175-180.	0.6	44
42	Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy?. Brain, 2016, 139, 2948-2956.	7.6	119
43	Distinctive neuronal firing patterns in subterritories of the subthalamic nucleus. Clinical Neurophysiology, 2016, 127, 3387-3393.	1.5	17
44	Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury. Acta Neuropathologica Communications, 2016, 4, 108.	5.2	27
45	Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. Journal of Translational Medicine, 2016, 14, 127.	4.4	41
46	Dementia in Parkinson's disease: Is male gender a risk factor?. Parkinsonism and Related Disorders, 2016, 26, 67-72.	2.2	52
47	Mechanical Energy Recovery during Walking in Patients with Parkinson Disease. PLoS ONE, 2016, 11, e0156420.	2.5	32
48	Movement Preparation and Bilateral Modulation of Beta Activity in Aging and Parkinson's Disease. PLoS ONE, 2015, 10, e0114817.	2.5	34
49	Characterization of the spiking and bursting activity of the subthalamic nucleus in patients with Parkinson's disease. , $2015$ , , .		2
50	Reply: Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2015, 138, e352-e352.	7.6	4
51	Parkinson's disease beyond 20â€years. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 849-855.	1.9	55
52	Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 278-86.	1.0	6
53	Gait Initiation in Children with Rett Syndrome. PLoS ONE, 2014, 9, e92736.	2.5	30
54	Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson $\tilde{A}$ ¢ $\hat{a}$ , $\neg \hat{a}$ , $\varphi$ s Disease. Frontiers in Aging Neuroscience, 2014, 6, 213.	3.4	21

#	Article	IF	Citations
55	Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors. Parkinsonism and Related Disorders, 2014, 20, 1382-1387.	2.2	93
56	Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study. Journal of Translational Medicine, 2014, 12, 14.	4.4	30
57	Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. Parkinsonism and Related Disorders, 2014, 20, 1181-1185.	2.2	3
58	Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2014, 137, 2480-2492.	7.6	169
59	Walking efficiency assessment through the analysis of mechanical energy and energy recovery index. , $2013, \dots$		0
60	Deep Brain Stimulation. , 2013, , 445-461.		2
61	[123I]FP-CIT SPECT in atypical degenerative parkinsonism. Imaging in Medicine, 2012, 4, 411-421.	0.0	3
62	The Influence of Dopaminergic Striatal Innervation on Upper Limb Locomotor Synergies. PLoS ONE, 2012, 7, e51464.	2.5	17
63	Artistic productivity and creative thinking in Parkinson's disease. European Journal of Neurology, 2012, 19, 468-472.	3.3	53
64	Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects. Neurolmage, 2011, 54, 1244-1253.	4.2	216
65	Pallidal Deep Brain Stimulation for Primary Dystonia in Children. Neurosurgery, 2011, 68, 738-743.	1.1	62
66	A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. Journal of Neurology, 2011, 258, 579-585.	3.6	113
67	Factors predicting protracted improvement after pallidal DBS for primary dystonia: the role of age and disease duration. Journal of Neurology, 2011, 258, 1469-1476.	3.6	101
68	Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurology, 2011, 11, 88.	1.8	46
69	Dopaminergic Striatal Innervation Predicts Interlimb Transfer of a Visuomotor Skill. Journal of Neuroscience, 2011, 31, 14458-14462.	3.6	32
70	A role for locus coeruleus in Parkinson tremor. Frontiers in Human Neuroscience, 2011, 5, 179.	2.0	51
71	Parkinsonian Tremor., 2011,, 64-72.		0
72	Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson's Disease. Neurodegenerative Diseases, 2010, 7, 319-329.	1.4	17

#	Article	IF	Citations
73	Imaging essential tremor. Movement Disorders, 2010, 25, 679-686.	3.9	80
74	Night-time use of rotigotine in advanced Parkinson's disease. Functional Neurology, 2010, 25, 201-4.	1.3	7
75	Deep Brain Stimulation for Primary Generalized Dystonia. Archives of Neurology, 2009, 66, 465-70.	4.5	180
76	Monoamine transporter availability in Parkinson's disease patients with or without depression. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 428-435.	6.4	72
77	Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: A prospective case-control study. Clinical Neurology and Neurosurgery, 2009, 111, 140-146.	1.4	40
78	Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. Parkinsonism and Related Disorders, 2009, 15, 327-328.	2.2	32
79	Safety of MRI in patients with implanted deep brain stimulation devices. Neurolmage, 2009, 47, T53-T57.	4.2	106
80	Imaging evidence supports a link between essential tremor and Parkinson's disease. Nuclear Medicine Communications, 2009, 30, 93-94.	1.1	7
81	Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study. European Journal of Neurology, 2008, 15, 22-28.	3.3	18
82	Loss of thalamic serotonin transporters in early drug-naÃ⁻ve Parkinson's disease patients is associated with tremor: an [123l]β-CIT SPECT study. Journal of Neural Transmission, 2008, 115, 721-729.	2.8	53
83	The relationship between impulsivity and impulse control disorders in Parkinson's disease. Movement Disorders, 2008, 23, 411-415.	3.9	131
84	[ <sup>123</sup> I]FPâ€CIT SPET imaging in drugâ€induced Parkinsonism. Movement Disorders, 2008, 23, 1825-1829.	3.9	47
85	Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. Movement Disorders, 2008, 23, 2049-2054.	3.9	35
86	A voxel-based PET study of dopamine transporters in Parkinson's disease: Relevance of age at onset. Neurobiology of Disease, 2008, 31, 102-109.	4.4	24
87	Parkin analysis in early onset Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 326-333.	2.2	42
88	Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration. Brain, 2008, 131, 1895-1902.	7.6	240
89	Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson's Disease. Neurodegenerative Diseases, 2008, 5, 244-246.	1.4	93
90	Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. Archives of Neurology, 2008, 65, 1604-11.	4.5	127

#	Article	IF	CITATIONS
91	Single photon-emission computed tomography imaging in early Parkinson's disease. Expert Review of Neurotherapeutics, 2008, 8, 1853-1864.	2.8	4
92	Striatal dopamine transporter abnormalities in patients with essential tremor. Nuclear Medicine Communications, 2008, 29, 349-353.	1.1	69
93	Deep Brain Stimulation Programming for Movement Disorders. , 2008, , 361-397.		15
94	[1231]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. NeuroReport, 2007, 18, 1499-1502.	1.2	59
95	Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: An ECD-SPECT study. Parkinsonism and Related Disorders, 2007, 13, 290-294.	2.2	61
96	Duodenal levodopa infusion for advanced Parkinson's disease: 12â€month treatment outcome. Movement Disorders, 2007, 22, 1145-1149.	3.9	241
97	Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. European Journal of Neurology, 2007, 14, 070206022829003-???.	3.3	11
98	Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. European Journal of Neurology, 2007, 14, 944-946.	3.3	14
99	LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism and Related Disorders, 2006, 12, 410-419.	2.2	106
100	Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. Movement Disorders, 2006, 21, 1144-1147.	3.9	41
101	Managing dystonia patients treated with deep brain stimulation. , 0, , 83-90.		1
102	Managing dystonia patients treated with deep brain stimulation. , 0, , 108-117.		1